Smokey, um, maybe not, as our fellow 'mite Plan-B would put it. (Generally prominent amidst the non-disclosure red ink that one deals with in this industry are interdictions against blogging, public on-line badinage, unapproved media interviewing, and so on. The clear import, veiled as protection of intellectual property, is concern about whistle-blowing.)
Anyway, I need to make something clear. I am not against medication. I'm nervous, being in an industry in which major problems with drugs and regimes in development and on the market are routinely "papered over," about the relatively little examined preoccupation in our lives these days with medicating where no threatening or even inconveniencing disease exists.
Most often nowadays, this comes in the form of arresting symptoms. If the symptom itself will kill or maim the patient, that's one thing. If the symptom is an inconvenience, that's something else. And the difficulty with "something else" is that neutralizing minor localized symptoms often places the body under greater pressure to surmount the invading pathogen with biologic workarounds that are potentially devastating. For someone like me who deals in etiological research it's part and parcel of what we do to understand many kinds of symptoms as, in fact, normal health-restorative responses to infection and injury. Inflammation is a perfect example: as a component of so-called "innate immune response," inflammation is a creation of your own biology to deal with a threat to its stability. It's not something that the pathogen or the traumatic event is doing. It's what your own body is doing to respond to that invasion or event.
Any time you treat even minor inflammation with an exogenous therapy (ibuprofen or aspirin, for example) you are by definition interfering with, and possibly stopping altogether, the organism's built-in defense against or compensation for whatever happens to be disturbing it. But healthy organisms don't just back off when their immediate, localized assault is interrupted; they go postal, as it were, driving system-wide countermeasures that end up being, in the long term, more dangerous than the original intrusion.
I wish I could feel more sanguine about modest treatments and therapies -- an antihistamine here, a prostaglandin-inhibitor there -- but I can't and don't. Because I see every day what happens when you press this kind of unbalancing strategy onto the self-correcting equilibria of homeostatic systems. Meanwhile, for those interested, I would suggest two books that will illuminate what sort of suspicion should be brought to bear. Both are available through Amazon and through library distribution catalogues like Link+.
http://www.amazon.com/Testing-Treatments-Imogen-Evans/dp/1905177356 ["Testing Treatments," Imogen Evans]
http://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Dstripbooks&field-keywords=big+pharma ["Big Pharma," Ben Goldacre]